Arndt Vogel: A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas

Arndt Vogel shared on X:

“A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas, European Journal of Cancer.

• Stopped at IA due to futility.
• Comparable activity, safety manageable.
• Not good, but both are options in 2nd line.”

Additional information.
Source: Arndt Vogel/X

Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School.

He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.